Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial

Clinical Snapshot

Key Findings

• P Value: P = 0.21

• Effect Size: 10.5% (tailored) vs 8.8% (standard DAPT)

• Primary Outcome: Composite of death, MI, stroke, stent thrombosis, urgent revascularization, and clinically relevant bleeding at 12 months

• Nnt Or Sensitivity: No benefit demonstrated; Number Needed to Harm for bleeding: 41 patients (based on 2.45% absolute increase)

• Confidence Interval: HR 1.19 (95% CI 0.90-1.58)

Clinical Application

Strategy requires careful timing of medication switches and patient compliance with complex regimen changes Relevant to Australian interventional cardiology practice; ticagrelor and clopidogrel both PBS-listed; aligns with current CSANZ guidelines for high-risk PCI patients High-risk patients undergoing complex PCI including left main, bifurcation lesions, diffuse disease, and multivessel intervention

Abstract

BACKGROUND AND AIMS: Limited data exist on optimal antiplatelet strategies for high-risk patients undergoing complex percutaneous coronary intervention (PCI). This study aimed to investigate the efficacy and safety of tailored antiplatelet treatment with temporal modulation of the intensity of platelet inhibition in patients undergoing complex high-risk PCI. METHODS: We randomly assigned 2018 patients with high-risk anatomical or clinical characteristics undergoing complex PCI to a tailored antiplatelet strategy with early escalation (low-dose ticagrelor at 60 mg twice daily plus aspirin <6 months) and late de-escalation (clopidogrel monotherapy >6 months) or dual antiplatelet therapy (clopidogrel plus aspirin for 12 months). The primary outcome was a composite of death from any cause, myocardial infarction, stroke, stent thrombosis, unplanned urgent revascularization, and clinically relevant bleeding (Bleeding Academic Research Consortium Type 2, 3, or 5) at 12 months. RESULTS: The mean age was 64.0 years, 22.6% had left main PCI, 19.5% had complex bifurcation PCI, 84.1% had diffuse long lesions, 93.7% had multivessel PCI, and 36.7% had medically treated diabetes. At 12 months, a primary outcome event occurred in 105 patients (10.5%) assigned to tailored antiplatelet therapy and in 89 patients (8.8%) assigned to dual antiplatelet therapy [hazard ratio, 1.19; 95% confidence interval (CI), 0.90-1.58; P = .21]. The incidence of major ischaemic events appeared to be similar in both groups. The incidence of clinically relevant bleeding at 12 months was 7.2% in the tailored-therapy group and 4.8% in the dual-therapy group (difference, 2.45% points; 95% CI, 0.37-4.53). CONCLUSIONS: Among high-risk patients undergoing complex PCI, tailored antiplatelet strategy with early escalation and late de-escalation, as compared with dual antiplatelet therapy, did not decrease the incidence of primary net adverse events at 12 months. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov number, NCT03465644.

References

1. 1.Kang, D. Y., Wee, S. B., Ahn, J. M., Park, H., Yun, S. C., Park, K. H., Kang, S. H., Suh, J., Bae, J. W., Park, S., Cho, J. H., Suh, J. W., Lee, B. K., Rha, S. W., Won, H., Jang, J. S., Cho, Y. R., Lee, C. H., Ahn, Y. K., Oh, J. H., Bae, J. S., Park, C. S., Lee, J. B., Choi, J., Lee, S. W., Her, S. H., Kwon, O., Park, S. J., & Park, D. W. (2026). Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. European Heart Journal. https://doi.org/10.1093/eurheartj/ehaf652